Everbridge, Inc., the global leader in High Velocity Critical Event Management™ (CEM) and national public warning solutions, today announced it has been awarded a new patent for AI-based technology ...
AI technology uses pattern recognition and predictive modeling to help organizations respond faster and smarter during emergencies
Patent reflects company’s leadership in AI innovation and $1 billion investment in High Velocity Critical Event Management
VIENNA, Va.: Everbridge, Inc., the global leader in High Velocity Critical Event Management™ (CEM) and national public warning solutions, today announced it has been awarded a new patent for AI-based technology designed to enhance the speed and precision of crisis response across its platform.
The newly granted patent covers the use of artificial intelligence to identify patterns in historical critical events and generate predictive models that support faster, more informed decisions during unfolding crises. These models are designed to help visualize threats, assess impact, and surface recommended actions, all within a unified analytics environment.
“This is what Everbridge innovation is all about,” said Bryan Barney, Chief Product Officer at Everbridge. “AI is how we continue to lead in this space and give organizations the power to stay ahead of fast-moving threats. This patent reinforces our commitment to delivering purpose-built AI that anticipates risk, recommends action, and improves outcomes.”
The patented capabilities align with enhancements planned for the Everbridge platform, including the type of predictive modeling already in use within xMatters. As the company continues to evolve its AI strategy, innovations like this will play a central role in helping organizations shift from reactive to proactive crisis management.
Continued Barney: “Over time, the system becomes smarter. Users will be able to provide context and annotations during or after an event, enriching the datasets available to the AI models, and making future predictions even more accurate and actionable.”
With this latest patent, Everbridge now boasts over 160 awarded patents, underscoring its leadership in AI, automation, and mission-critical resilience solutions. It also reflects the company’s $1 billion investment in delivering High Velocity CEM, enabling organizations to know earlier, respond faster, and improve continuously in the face of today’s most complex threats.
About Everbridge
Everbridge is the global leader in Critical Event Management (CEM), helping organizations achieve a true business resilience advantage. With Everbridge High Velocity CEM, our customers accelerate response times, minimize disruption, and maintain operational control amid today’s most complex threats. Using purpose-built AI, decision-ready risk intelligence, and full lifecycle automation, Everbridge enables organizations to know earlier, respond faster, and improve continuously with confidence. For more information, visit everbridge.com, read the blog, and follow us on LinkedIn.
Everbridge... Keeping People Safe and Organizations Running™
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Paycom Software, Inc. (“Paycom,” “we” and “our”) (NYSE: PAYC), a leading provider of comprehensive, cloud-based human capital management software, today…
As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing…
Mogo Inc. (NASDAQ:MOGO) (TSX:MOGO) (“Mogo” or the “Company”), a digital wealth and payments business, today announced that it will be participating in…
Nanyang Biologics (NYB) and Precisya Global Inc (PGI) announce a strategic collaboration to leverage our technologies in validating potential therapeutic…